CD200R3, Mouse, mAb Ba91
The monoclonal antibody Ba91 recognizes mouse CD200 Receptor-like 3 (CD200R3), a protein of ~38 kDa or ~74 kDa (reduced or non-reduced condition, respectively). CD200R3 presumably exists as a disulfide-linked dimer on the cell surface. The OX-2, or CD200 receptor (CD200R), belongs to the immunoglobulin superfamily. CD200R contains two Ig-like extracellular domains and mediates inhibitory signals in myeloid cells. Mice deficient for the ligand CD200 develop enhanced experimental allergic encephalomyelitis and collagen-induced arthritis. Unlike CD200R, the CD200R-like receptors functions as activating receptors. They contain short cytoplasmic tails and a lysine residue in the transmembrane region and are likely to signal via adaptor proteins such as DAP12, DAP10, FcRg, or CD3z. CD200R3 is expressed preferentially on cells of the myeloid lineage, including mast cells and basophils. Both cell types are involved in the host defense system against pathogens and in the development of allergic disorders. They function as independent essential initiators of allergic reactions. Basophils are the least common leukocytes in the peripheral blood accounting approximately 0.5 % of all leukocytes. In vivo depletion of basophils by using monoclonal antibody proved the essential role of basophils in the development and maintenance of IgE-mediated chronic allergic inflammation. The activating CD200 receptors, like CD200R3, play an important role in IgE-independent mast cell and basophil activation. Monoclonal antibody Ba91 activates basophils ex vivo and elicits systemic anaphylaxis when administered in vivo. Cross-linking of CD200R3 on MC/9 cells by monoclonal antibody Ba91 induces degranulation. Monoclonal antibody Ba91 is also useful for depletion of basophils.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA